Log In
BCIQ
Print this Print this
 

4SC-205

  Manage Alerts
Collapse Summary General Information
Company 4SC AG
DescriptionOral inhibitor of kinesin spindle protein (KSP; Eg5; TRIP5)
Molecular Target Kinesin spindle protein (KSP) (Eg5) (KIF11)
Mechanism of ActionKinesin spindle protein inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerLink Health Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$84.5M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/31/2016

$84.5M

Undisclosed

Undisclosed

Get a free BioCentury trial today